Project leader - main PI:
Co-PI
Researchers
Project period: 2022-06-01 to 2022-12-31
Funding: Marcus and Amalia Wallenberg Foundation
Melanoma is the most dangerous type of skin cancer as it spreads to other organs more rapidly if not treated at an early stage. Treatment is typically surgical, with only a small group of metatastatic patients receiving chemotherapy and/or interferon therapy. About 80% of patients survive melanoma but remain at risk for disease progression for many years, for which there is no successful therapy, making melanoma a chronic, life-threatening and QoL-affecting disease and melanoma patients a patient group most likely to benefit from the AI-enhanced PROMs-based monitoring of ASME.
The goal of ASME is to extend the existing ASCAPE datasets with an ASCAPE-ready melanoma patient dataset to enable both standard ASCAPE and ASME-proposed AI/ML algorithms (for model training, predictions, analytics and simulations) on a type of cancer not originally supported by ASCAPE.
The main objectives of ASME are:
ASME’s work will center around Stockholm University’s retrospective dataset containing data of approximately 250 melanoma patients. Its aims will be to: